Accelerated development of KRAS G12C targeted therapies at #ASCO24 #lcsm OncoAlert

Dr. James Yang #ASCO24 shows WU-KONG1 primary analysis of sunvozertinib (DZD9008) in #EGFR NSCLC. Explored 200mg vs 300mg daily, 300mg selected to go forward.

Dr. John Heymach #ASCO24 with updated data from phase I study of BEAMION Lung-1, zongertinib (BI 1810631) in pts with #HER2 tumors including NSCLC. RR in NSCLC 44%, RR 36% post T-DXd.

WU-KONG1B: Sunvozertinib in 2L+ EGFR Ex20 Ins

🤜 ORR 44%
🤜 mDoR not reached; 9m DoR 57%
🤜 Gr3+ AE = diarrhoea (17% ⬆️ CPK 10%, ILD 3%

🤔 Great to see an active Ex20 TKI
🤔 Well tolerated compared to 1G TKIs
🤔 Ph3 trials ongoing

👏

#ASCO24 #LCSM

Sunvozertinib in pretreated NSCLC with Exon 20 EGFR insertions at #ASCO24 OncoAlert

Moving beyond current immunotherapy in Lung Cancer at #ASCO24 #lcsm OncoAlert Ben Creelan, MD

KRYSTAL 12 Trial: Adagrasib vs Docetaxel in pretreated advanced NSCLC KRAS G12C mut+ presented at #ASCO24 by Tony Mok OncoAlert

Really pleased to see this trial outcome that builds on IMP150 and ORIENT31 and ATTLAS. PD1 alone is inadequate, because also needed. Q is if to use an IO-beva regime or an ami-based regime on osi OD. #ASCO24

#ASCO2024 : Fase 1/2 demonstrando segurança e efetividade promissora de Olomorasib (iKRAS G12C 2a ger. 50-100mg) + Pembro, CPCNP avanç. mKRAS, q/q linha tto (incl. iKRAS e IO). ORR = 77% em 1L e 40% em prev. tratados. Princ. EA = diarreia, ⬆️AST/ALT. Trial 1L SUNRAY-01 recrutando

Current targeted therapies for advanced Non Small Cell Lung Cancer with genomic alterations at #ASCO24 #lcsm OncoAlert

#ASCO24

Ph II KROCUS trial of 1L fulzerasib + cetuximab:

- 81.8% ORR, 40 pts
- mild tox, mainly skin
- response across PDL1 subsets

Intriguing data, but no prior PD1 or concurrent PD1 with chemo in 1L?

ASCO ESMO - Eur. Oncology IASLC OncoAlert #LCSM

POP QUIZ: Is this a waterfall plot for a new lung cancer TKI? Nope…SEZ6 ADC for Relapsed Small Cell Lung Cancer (and other NECs). #SCLC #LCSM . MD Anderson Cancer Center Thank you to the study team and all of our investigators, patients and families. ASCO #ASCO24

KROCUS: Fulzerasib (KRAS G12Ci) +cetuximab. Combo is synergistic in vitro. N=40 treatment naive. ORRi= 82%, incl its with CNS disease (ORR 70%). G3+ TRAEs 17.5%. DRs 2.1%. Main AEs rash>asthenia>pruritus. N=14, ORR unrelated to EGFR expression #ASCO24

Sacituzumab tirumotecan + KL-A167 (anti-PD-L1) as 1st line Tx in aNSCLC (OptiTROP-Lung01).

ORR=48.6% in cohort 1A (Q3W), 77.6% in cohort 1B (Q2W)
mPFS=15.4 mo in cohort 1A, NR for cohort 1B

Phase 3 study SKB264 (Q2W) + pembro vs. pembro in mNSCLC with PD-L1 ≥ 50% ongoing.

CODEBREAK 101; Sotorasib (G12Ci) + platinum doublet(carbo pem x4>maintenance); ORR 65% in Tx naïve and 42% in pretreated. mPFS 10.8m in in treated and 8.3m in pretreated. #ASCO24

1stG KRAG12Ci (sotirasib and adagrasib) reached a plateau RR~35% PFS ~6 mo. Monotherapy not enough. Next step is moving to move to 1st L in combo with immuno or cetuximab such as fulzerasib 600 mg BID cetux. 500 mg/m2 Q2W➡️ RR 81% Future of KRAS strategy is combo approach #ASCO24

ICARUS Lung 01 trial from Gustave Roussy focused on resistance mechanisms to ADCs seems to confirm different Dato-Deruxtecan according histology but no driver alteration identified as potential predictive factor at #ASCO24 #lcsm OncoAlert

Dr. Luis Paz-Ares presents the phase III EVOKE-01 trial: sacituzumab govitecan (Trop2 ADC) vs docetaxel in previously treated NSCLC. ~65% pts non-responsive to prior immunotherapy. Study did not meet primary endpoint of OS in ITT (11.1m vs 9.8m, HR 0.84, ns) #ASCO24

KROCUS; Fulzerasib (G12Ci) + cetuximab; n= 40 Tx naïve; ORR 82% (icORR 70%); quick and deep responses; impressive tolerability ; #ASCO24

#ASCO24
EVOKE-01 study: SG vs docetaxel

mPFS➡️4.1 vs 3.9 mo (NS)
mOS➡️11.1 vs 9.8 mo (NS)

💥SG was not superior to docetaxel in patients previously receiving platinum and ICI

Presented by dr. Luis G. Paz-Ares
OncoAlert